Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well vorinostat works in treating patients with
metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.